AdvisorShares Psychedelics ETF

Bright Minds Biosciences released FY2026 Semi-Annual Earnings on May 19 (EST), actual revenue USD 0, actual EPS USD -1.506

Bright Minds Biosciences released FY2026 Q2 earnings on May 19, 2026 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -0.7829 (forecast USD -0.9535)

Neurocrine Biosciences advances Phase II clinical trial for NBI-1065890

UCB's Bimzelx Beats AbbVie's Skyrizi in Head-to-Head Psoriatic Arthritis Study with Superior Joint Outcomes

The Hill and Definium Therapeutics Host Forum on Psychedelic Therapy Prospects

AtaiBeckley Reports Q1 Net Loss of $29.78M, Stock Rises Amid Valuation Debate

Neurocrine Biosciences Director Richard F. Pops Sells 15,000 Shares for $2.36 Million

Neurocrine Biosciences Releases Real-World Data Confirming INGREZZA's Improvement in Tardive Dyskinesia

Multiple Brokerages Adjust AbbVie Ratings as Q1 Earnings Beat Expectations

H.C. Wainwright Analyst Trucchio Maintains Buy Rating on COMPASS Pathways, Sets Target Price at $70

Mubadala Increases Stakes in AbbVie and Match Group, Reduces CVS and Gilead Holdings in Q1

NRX Therapeutics released FY2026 Q1 earnings on May 15 Pre-Market (EST), actual revenue USD 1.068 M (forecast USD 19.43 M), actual EPS USD -0.0442 (forecast USD 0.208)

AbbVie's Ekali approved by NMPA for combination therapy in R/R follicular lymphoma

GH Research released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3057 (forecast USD -0.2633)

Compass Pathways Submits Psilocybin Drug COMP360 for New Drug Application

Compass Pathways released FY2026 Q1 earnings on May 13 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0.7001 (forecast USD -0.4472)

COMPASS Pathways plc Reports Q1 2026 Financials

AtaiBeckley released FY2026 Q1 earnings on May 12 (EST), actual revenue USD 954 K (forecast USD 90.91 K), actual EPS USD -0.0833 (forecast USD -0.1087)

Relmada Therapeutics released FY2026 Q1 earnings on May 12 During-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.22 (forecast USD -0.195)

Alkermes Announces Positive Top-Line Results for Lumryz® in Adult Idiopathic Hypersomnia Phase III Study

Co-Diagnostics

NewGenIvf

Liminatus Pharma

Agape ATP

Tradr 2X Long QBTS Daily ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Netcapital

Wheeler Real Estate

CMPS

ATAI

CYBN

PSIL

Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?

Barchart Option

Compass Pathways

AtaiBeckley

Cybin

Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?

The article discusses the current state of cannabis investments and suggests considering psychedelics stocks instead. Cannabis stocks have faced challenges due to oversupply and regulatory uncertainties, leading to cautious sentiments among investors. Doug Kass, a trader, has exited most cannabis holdings, citing long-term risks. Meanwhile, psychedelics stocks are gaining attention following an executive order to accelerate research on substances like psilocybin. However, these stocks are also risky, often being small caps with low trading volumes. Investors are advised to approach with caution and consider ETFs like AdvisorShares Psychedelics ETF (PSIL).

Tip Ranks

AdvisorShares Pure US Cannabis ETF

Beyond Cannabis: 3 Stock Picks Tied to the Psychedelics Trade

ANRO

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression | ANRO Stock News

StockTitan

Alto Neuroscience

SPDR Pharmac

iShares Biotechnology ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

iShares US Medical Devices

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

iShares Neuroscience And Healthcare ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Direxion Pharma & Medical Bull 3X

iShares Global Healthcare

iShares US Pharma

VG Health

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression | ANRO Stock News

MNMD

President Donald Trump has signed an Executive Order to accelerate access to treatments for serious mental illness. The Order directs the FDA to provide National Priority Vouchers for psychedelic drugs with Breakthrough Therapy designations, ensuring timely reviews and reducing delays in therapy access for patients with complex conditions.

rttnews

Mind Medicine MindMed

Trump Order To Accelerate Treatments For Serious Mental Illness

SILO

Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics | SILO Stock News

Silo Pharma

Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics  | SILO Stock News

IXHL

Incannex Healthcare aligns its PSX-001 program with a White House Executive Order, highlighting strong Phase 2 data that shows a significant reduction in anxiety symptoms. The Phase 2 trial reported a 12.8-point reduction in HAM-A scores compared to 3.6 for placebo, with a 44% clinically meaningful response and 27% remission sustained for 11 weeks. The company has over $70 million in cash, no debt, and an active U.S. IND, positioning it well for advancement amid regulatory changes.

TradingView

Incannex Healthcare

Incannex Healthcare aligns PSX-001 program with White House order, cites strong Phase 2 data and $70M cash

The recent surge in interest in psychedelic stocks is linked to President Trump's executive order aimed at enhancing research and access to drugs like psilocybin and MDMA for treating mental illnesses. However, investing in these stocks carries risks due to their small market caps and low trading volumes, which can lead to wider spreads and potential profitability issues. The popularity of these stocks may also be fleeting, reminiscent of the decline seen in marijuana stocks, as exemplified by Tilray Brands' significant loss in value over the past five years.

Tilray Brands

3 Different Ways to Play the Rally in Psychedelic Stocks

The FDA has granted Compass Pathways a rolling review for its New Drug Application (NDA) for COMP360, a psychedelic therapy for treatment-resistant depression (TRD). This designation could expedite the review process to one to two months post-filing. Compass has reported positive results from two Phase 3 trials involving over 1,000 participants, indicating significant effects and manageable safety profiles. The decision reflects a growing regulatory interest in innovative treatments for mental health disorders, particularly for patients with limited options. The next step involves completing the NDA under the rolling review framework, with approval contingent on clinical evidence and product quality.

Pharmexec

<![CDATA[FDA Awards Priority Voucher to Compass for Psychedelic Therapy in Treatment-Resistant Depression]]>

Trump's recent executive order aims to expedite the review of psychedelic therapies, potentially attracting institutional investment. Compass Pathways, currently in phase 3 testing with promising data, stands out in the psychedelics sector. With $150 million in cash, the company is well-positioned to reach a regulatory decision without immediate dilution. Its lead asset, COMP360, shows significant efficacy for treatment-resistant depression. Compass has demonstrated strong institutional backing, owning 46% of its shares, and is funded to advance its late-stage development, although risks remain tied to regulatory approval and commercialization.

AdvisorShares Psychedelics ETF(PSIL.US)

Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?

Beyond Cannabis: 3 Stock Picks Tied to the Psychedelics Trade

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression | ANRO Stock News

Trump Order To Accelerate Treatments For Serious Mental Illness

Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics | SILO Stock News

Incannex Healthcare aligns PSX-001 program with White House order, cites strong Phase 2 data and $70M cash

3 Different Ways to Play the Rally in Psychedelic Stocks

<![CDATA[FDA Awards Priority Voucher to Compass for Psychedelic Therapy in Treatment-Resistant Depression]]>

Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About

Trump: Accelerate access to research on psychedelic drugs